Results 51 to 60 of about 17,995 (248)

Movement Disorders Associated with 22q11.2 Microdeletion: A Scoping Review

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Movement disorders have recently emerged as important neurologic manifestations of the 22q11.2 microdeletion that affects nearly one in every 2000 live births. Objective We aimed to map the existing evidence regarding the spectrum, diagnosis and treatment, and etiopathogenesis of movement disorders associated with 22q11.2 ...
Nikolai Gil D. Reyes, Daniel G. Di Luca, Connie Marras, Erik Boot, Ryan K.C. Yuen, Anthony E. Lang, Anne S. Bassett   +6 more
wiley   +1 more source

Effects of dance therapy on balance, gait and neuro-psychological performances in patients with Parkinson's disease and postural instability [PDF]

, 2012
Postural Instability (PI) is a core feature of Parkinson’s Disease (PD) and a major cause of falls and disabilities. Impairment of executive functions has been called as an aggravating factor on motor performances. Dance therapy has been shown effective
Agnetti, Virgilio, Aiello, Elena, De Natale, Edoardo, Deriu, Franca, Paulus, Kai Stephan, Sotgiu, Giovanni, Tolu, Eusebio   +6 more
core  

Medication Knowledge of Patients with Parkinson's Disease: Strengths and Gaps

Movement Disorders Clinical Practice, EarlyView.
Abstract Background Effective drug treatment of motor and non‐motor symptoms in Parkinson's disease (PD) often requires the administration of several anti‐Parkinson drugs in complex treatment regimens. The successful autonomous application of drugs places high demands on therapy adherence, which in turn relies on sufficient medication knowledge ...
Stephan Greten, Sarana Ulaganathan, Johannes Heck, Lan Ye, Matthias Höllerhage, Christoph Schrader, Corinna Ziemann, Olaf Krause, Florian Wegner, Martin Klietz   +9 more
wiley   +1 more source

LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature

Brain and Behavior, 2020
Background For managing nonmotor symptoms (NMS) in advanced Parkinson's disease (PD), levodopa–carbidopa intestinal gel (LCIG) infusion is of interest as it shows lesser plasma fluctuations of both drugs as compared to oral levodopa–carbidopa (LC ...
Walaa A. Kamel, Jasem Y. Al‐Hashel
doaj   +1 more source

Considerations for Initiation and Maintenance of Foslevodopa/Foscarbidopa for Advanced Parkinson's Disease

Movement Disorders Clinical Practice, EarlyView.
Abstract Background As Parkinson's disease (PD) progresses, motor fluctuations become increasingly difficult to manage with oral medications. Foslevodopa/foscarbidopa (LDp/CDp), delivered as a continuous 24‐h/day subcutaneous infusion, offers continuous levodopa delivery and stable plasma levodopa levels that reduce motor fluctuations. LDp/CDp has been
K. Ray Chaudhuri, Bruno Bergmans, Eric Freire‐Alvarez, Lucie Hopes, Drew S. Kern, Robert S. Kirsner, Giulia Lazzeri, Pedro Mendes‐Bastos, Noriko Nishikawa, Per Odin, Karolina Poplawska‐Domaszewicz, Rajesh Pahwa, Yuval Ramot, Klaus Seppi, Tobias Warnecke, Robert Wiggins, Megha B. Shah, Pavnit Kukreja, Bjoern Fritz, Koray Onuk, Stuart H. Isaacson   +20 more
wiley   +1 more source

Chemometric Determination of Parkinson's Drugs Containing Multiple Active Substances

Cumhuriyet Science Journal
In this work, the active ingredients of Entacapone, Levodopa and Carbidopa in drug samples used in the treatment of Parkinson's disease were quantitatively determined by Ultraviolet Visible (UV-VIS) Spectroscopy and chemometrics.
Ayşe Merve Arslan, Güzide Pekcan
doaj   +1 more source

Long-Term Intravitreal Ranibizumab as a Potential Additional Risk Factor for Neurodegeneration in Parkinson's Disease: A Case Report. [PDF]

, 2018
In November 2012, a 72-year old patient was diagnosed with left eye wet age-related macular degeneration. The patient received three monthly intravitreal injections of ranibizumab, with complete resolution of retinal hemorrhage and edema and ...
Antonini, Bodis-Wollner, Brilliant, Brown, Chung, Cutroneo, de Jong, Ding, Drake, Enders, Falk, Gibson, Kemp, Krum, Miners, Naranjo, Nowacka, Nowacka, Piltonen, Pitzer, Poewe, Postuma, Pratt, Quittet, Rosenfeld, Shamloo, Sheikh, Silverman, Slotnick, Stewart, Storkebaum, Tian, Trost, Ueta, Whitton, Wu, Yasuda, Yasuhara, Yasuhara, Yasuhara, Yla-Herttuala, Yue, Zachary, Zehetner   +43 more
core   +2 more sources

Altered Dopamine Metabolism and Response to Treatment with Levodopa/Carbidopa in MCT8 Deficiency

Movement Disorders, EarlyView.
Abstract Background Allan‐Herndon‐Dudley syndrome (AHDS)/monocarboxylate transporter 8 (MCT8) deficiency is a rare X‐linked encephalopathy caused by SLC16A2 variants, impairing thyroid hormone (TH) transport into the brain. This leads to early central nervous system (CNS) TH deficiency, affecting brain maturation.
Fabio Bruschi, Ylenia Vaia, Clara E. Antonello, Marco Spada, Francesco Porta, Cristina Marinaccio, Claudia Carducci, Thomas Opladen, Jacopo Sartorelli, Federica Maria Zibordi, Daniele Ghezzi, Francesco Nicita, Davide Tonduti   +12 more
wiley   +1 more source

Parkinson’s Disease Managing Reversible Neurodegeneration [Expression of Concern]

Neuropsychiatric Disease and Treatment, 2020
Hinz M, Stein A, Cole T, McDougall B, Westaway M. Neuropsychiatr Dis Treat. 2016;12:763–775. The Editor-in-Chief and Publisher of Neuropsychiatric Disease and Treatment wish to issue an Expression of Concern for the published article.
Hinz M, Stein A, Cole T, McDougall B, Westaway M   +4 more
doaj  

Management of rapid eye movement sleep behavior disorder in patients with Parkinson's disease [PDF]

, 2016
Among all of the devastating effects that Parkinson’s disease (PD) has on an individual, sleep dysfunction is one that can have a profound effect on the entire family of the patient. The most potentially destructive of these sleep syndromes being that of
Jeffries, Michael
core   +1 more source